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Adenoid cystic carcinoma of the Bartholin's gland has been encountered 
in 11 patients at the University of Michigan Medical Center since 1936. 
At the time of presentation the average age was 48.9 years, the lesion size 
was between 0.5 to 4 cm. The presenting symptoms were pain and/or 
pruritis associated with a solitary mass. Early in this series, excisional 
biopsy was used to treat eight patients. The last three patients have been 
treated with a radical vulvectomy and unilateral or bilateral groin lymph 
node dissection. Local recurrence has occurred in five patients and 
distant recurrence in four patients. In spite of the high recurrence rate, 5- 
and 10-year survival has been high with all seven evaluable patients 
surviving 5 and 10 years. However, adenoid cystic carcinoma of the vulva 
is associated with late recurrences and metastases: three patients were 
dead of disease at 12, 15 and 31 years after initial diagnosis. 
KEYWORDS: adenoid  cystic carcinoma, Bartholin 's  gland, vulvar  
malignancy. 
Vulvar carcinoma is the fourth most common female 
genital tract malignancy. Among vulvar neoplasms, an 
estimated 5% are of Bartholin's gland origin. Adeno- 
carcinoma or squamous cell carcinoma account for 
90% of these Bartholin's gland neoplasms. The remain- 
ing types include adenoid cystic carcinomas, melano- 
mas, sarcomas, and undifferentiated neoplasms. 
Adenoid cystic carcinoma histologically exhibits a 
classical cribriform arrangement of tubal and gland- 
ular elements. Perineural and lympathic invasion is 
characteristic of this tumor, and may explain its 
propensity for causing pain and recurrence. 
Copeland et al. reported (1) five patients with primary 
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adenoid cystic carcinoma of the Bartholin's gland, and 
reviewed 32 additional cases from the literature. Over- 
all, long-term survival was excellent. However, there 
was a propensity for frequent ipsilateral vulvar recur- 
rence. This is in contrast to the more common extra- 
genital adenoid cystic carcinoma which lends itself to 
adequate therapy and a long disease free interval. 
This study was undertaken to evaluate our exper- 
ience at the University of Michigan Medical Center 
with this rare genital malignancy. 
P a t i e n t s  a n d  m e t h o d s  
A review of the UMMC Tumor Registry was under- 
taken to identify all patients with a diagnosis of 
adenoid cystic carcinoma of the Bartholin's gland seen 
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between 1936 and 1991. The criteria for the diagnosis 
of primary Bartholin's gland carcinoma include: tumor 
involving the area of the Bartholin's gland, histologic 
area of transition from normal to neoplastic elements, 
and no other primary carcinoma present (E) . 
Pathologic slides from patients were reviewed at the 
Gynecologic Tumor Conference to confirm the diag- 
nosis of adenoid cystic carcinoma. Patient records 
were reviewed for clinical information, and follow-up 
was available through the Tumor Registry. 
Results 
Eleven patients with adenoid cystic carcinoma of the 
Bartholin's gland were identified (Table 1). Four of 
these patients were reported previously by Abell (3). 
The most common presenting symptoms were pain 
and /o r  pruritis associated with the physical finding of 
solitary mass in the region of the Bartholin's gland. 
The median age at diagnosis was 48.9 years (range 
from 38 to 63 years). The size of the primary lesion 
ranged from 0.5 to 4 cm. The initial therapeutic ap- 
proach included excisional biopsy, i.e. resection of the 
visible lesion with minimal margins (n =7), partial 
vulvectomy (n = 1), and radical vulvectomy with groin 
lymph node dissection (n = 3). Follow-up data were 
available for nine patients. The time of observation 
ranged from one to 31 years (median 12 years). 
Five of the eleven patients developed local recur- 
rence with a median progression-free interval of 8 
years (range 2-13 years). Distant recurrence was diag- 
nosed in four patients after 11, 15 and 16 years. The 
site of distant recurrence included lung, bone, liver, 
and lymph nodes. One patient (#4) had isolated pul- 
monary metastases. Another patient, (#7) showed lung 
and pubic bone involvement with positive pelvic 
lymph nodes, while local bone metastases (ilium and 
femoral head) were confirmed for a third patient (#6). 
Skeletal metastases outside the pelvis were not identi- 
fied in any of these ten patients. One patient (#8) devel- 
oped both lung and liver metastases. Six out of the 
eleven patients in this series have died. Three patients 
died from systemic spread of the vulvar malignancy. 
Two patients died of causes not related to the vulvar 
malignancy and in one patient the cause of death is 
unknown. All three patients who died from the disease 
had developed local recurrences with subsequent pul- 
monary metastases, in two patients in conjunction 
with spread to bone (#7) and liver (#8), respectively. 
Five patients had disease to surgical margins, and 
one of these developed a local recurrence. Of the four 
patients who had negative margins, all four developed 
a recurrence. 
Discussion 
Five of the 11 patients presented in this report de- 
veloped local recurrence. There was a long interval 
between the initial diagnosis of the disease and pro- 
gression. The median time interval of eight years 
reported here agrees with that summarized in the 
literature °). There also appears to be a propensity for 
local recurrences prior to the development of distant 
metastases. Copeland et al. (1) and Bernstein et al. (4) 
point out, that the most important aspect of treatment 
is to obtain clear surgical margins. However, in our 
review of the eleven patients treated at the University 
of Michigan Medical Center, the local recurrence rate 
did not appear to be influenced by the presence or ab- 
sence of disease at the surgical margins. All four 
patients who had negative margins at the time of 
primary surgery developed a local vulvar recurrence. 
This could be due to early local dissemination of tumor 
cells beyond the margin of resection. In adenoid cystic 
carcinomas, the tumor grows along the nerve roots, 
and this might not be recognized histologically. In 
contrast, only one of the five patients with positive 
margins (#7) developed a recurrence after a disease- 
free interval of eight years. It can be speculated that the 
follow-up intervals for three of the remaining four 
patients, who had positive margins at the time of first 
treatment, were too short to let a local recurrence 
become evident: one of these patients (#3) was from 
the earlier series and was lost to follow-up after 3 
years, and the other two patients (#10 and #11) were 
diagnosed more recently (in 1985 and 1989). 
The above observations seem to suggest that event- 
ually all patients will develop a recurrence regardless 
of resection margin at the time of initial therapy. How- 
ever, in some patients the disease-free interval will be 
longer than the natural life expectancy, so that the 
patient will die from causes other than the recurrent 
vulvar malignancy. 
The number of patients in this report is small and 
statistically reliable data on the natural history of 
adenoid cystic carcinoma of the vulva are not avail- 
able. Therefore, the necessity of a wide local resection 
to obtain free margins should not be dismissed. 
However, radical resections with considerable mor- 
bidity do not appear to be justified either. These 
should be reserved for the larger lesions or when 
disease is expected to extend into the ischiorectal 
fossa. 
Fifteen patients reported in the literature have un- 
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dergone groin node dissections and only two were 
found to have metastatic disease (1). Both of these were 
located on the ipsilateral side of the vulvar neoplasm. 
One of the patients reported here (#7) developed 
positive pelvic lymph nodes. However,  these were not 
diagnosed until 11 years after the primary therapy at 
the time of a second recurrence. None of the three 
patients who  underwent  unilateral or bilateral groin 
lymph node dissection had positive nodes. The limited 
evidence that is available in the literature (~) suggests 
that a groin lymph node dissection can be limited to an 
ipsilateral dissection as the disease has not yet been re- 
ported to involve the contralateral lymph nodes. With 
only 10% of lymph nodes positive, the dissection may  
be reserved for those patients felt to be at high risk for 
nodal  involvement. 
The metastatic spread of this neoplasm appears to 
occur by the hematogenous and geographic route. The 
hematogenous pa thway appears a likely mechanism 
for those patients with lung and bony metastasis, 
whereas direct extension along the neural sheath may  
be responsible for frequent local recurrences. This 
spread pattern appears similar to that of primary 
adenoid cystic carcinoma from other anatomic sites, 
such as the glands of the neck {5), upper  respiratory 
tract (6), and breast (7). 
Chemotherapy has been utilized for metastatic 
adenoid cystic carcinoma of the salivary (5) and par- 
otid gland (8). There is little information available on its 
use in the female genital tract. One patient (#8), re- 
ceived cyclophosphamide as an adjuvant therapy after 
wide excision of a recurrence in the labium. She died 
15 years after initial diagnosis from wide-spread 
metastatic disease. Other reports of chemotherapeutic 
treatment of metastatic adenoid cystic carcinoma of 
the Bartholin's gland include a combination of metho- 
trexate, Dactinomycin, and chlorambucil (9) or doxoru- 
bicin therapy (1°). Further evaluation of chemotherapy 
regimens for treatment of recurrent diseases are 
needed to evaluate its efficacy for known metastasis. 
However, due to the extended interval to recurrence it 
will be difficult to show any benefit for this adjuvant 
therapy. 
Copeland et al. (1) reported a survival rate of 71 and 
59% for 5 and 10 years, respectively. In the present 
series 5- and 10-year survival was 100%, as the three 
patients who died of the disease lived for 12, 15 and 31 
years after the initial diagnosis. The disease-free inter- 
val for the patients in Copeland's series was 47% at 5 
years and 38% at 10 years as compared with 83% (five 
out of six patients) and 33% (two out of six patients) in 
the present study. 
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